Generic placeholder image

Current Molecular Pharmacology

Editor-in-Chief

ISSN (Print): 1874-4672
ISSN (Online): 1874-4702

General Review Article

Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer

Author(s): Jinku Zhang, Jirui Sun, Sahar Bakht and Waseem Hassan*

Volume 15, Issue 1, 2022

Published on: 03 August, 2021

Article ID: e080621193950 Pages: 11

DOI: 10.2174/1874467214666210608141102

Price: $65

Abstract

Prostate cancer (PC) is a rapidly increasing ailment worldwide. The previous decade has observed a rapid advancement in PC therapies that was evident from the number of FDA approvals during this phase. Androgen deprivation therapies (ADT) have traditionally remained a mainstay for the management of PCs, but the past decade has experienced the emergence of newer classes of drugs that can be used with or without the administration of ADT. FDA approved poly (ADP-ribose) polymerase inhibitors (PARPi) such as olaparib and rucaparib after successful clinical trials against gene-mutated metastatic castration-resistant prostate cancer. Furthermore, drugs like apalutamide, darolutamide and enzalutamide with androgen-targeted mechanism of action have manifested superior results in non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration- sensitive prostate cancer (mCSPC), and metastatic castration-resistant prostate cancer (m- CRPC) respectively with or without previously administered docetaxel. Relugolix, an oral gonadotropin- releasing hormone antagonist and a combination of abiraterone acetate plus prednisone were also approved by FDA after a successful trial in advanced PC and mCRPC respectively. This review aims to analyze the FDA-approved agents in PC during last decade and provide a summary of their clinical trials. It also presents an overview of the ongoing progress of prospective molecules still under trial.

Keywords: Prostate cancer, relugolix, apalutamide, darolutamide, enzalutamide, molecular targeted therapy.

Graphical Abstract

[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(1), 7-30.
[http://dx.doi.org/10.3322/caac.21590] [PMID: 31912902]
[2]
Grozescu, T.; Popa, F. Prostate cancer between prognosis and adequate/proper therapy. J. Med. Life, 2017, 10(1), 5-12.
[PMID: 28255369]
[3]
Gottschalk, A.R.; Roach, M., III The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br. J. Cancer, 2004, 90(5), 950-954.
[http://dx.doi.org/10.1038/sj.bjc.6601625] [PMID: 14997188]
[4]
Dai, C.; Heemers, H.; Sharifi, N. Androgen Signaling in Prostate Cancer. Cold Spring Harb. Perspect. Med., 2017, 7(9), a030452.
[http://dx.doi.org/10.1101/cshperspect.a030452] [PMID: 28389515]
[5]
Komura, K.; Sweeney, C. J.; Inamoto, T.; Ibuki, N.; Azuma, H.; Kantoff, P. W. Current treatment strategies for advanced prostate cancer. Int. J. Urol., 2018, 25(3), 220-231.
[http://dx.doi.org/10.1111/iju.13512]
[6]
Abiodun-Ojo, O. A.; Akintayo, A. A.; Akin-Akintayo, O. O.; Tade, F. I.; Nieh, P. T.; Master, V. A.; Alemozaffar, M.; Osunkoya, A. O.; Goodman, M. M.; Fei, B.; Schuster, D.M. (18)f-fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer. J. Nucl. Med., 2019, 60(11), 1531-1536.
[http://dx.doi.org/10.2967/jnumed.119.227033] [PMID: 30954940]
[7]
Alemozaffar, M.; Akintayo, A.A.; Abiodun-Ojo, O.A.; Patil, D.; Saeed, F.; Huang, Y.; Osunkoya, A.O.; Goodman, M.M.; Sanda, M.; Schuster, D.M. [18F]Fluciclovine positron emission tomography/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancer. J. Urol., 2020, 204(4), 734-740.
[http://dx.doi.org/10.1097/JU.0000000000001095] [PMID: 32347780]
[8]
Movahedi, P.; Merisaari, H.; Perez, I.M.; Taimen, P.; Kemppainen, J.; Kuisma, A.; Eskola, O.; Teuho, J.; Saunavaara, J.; Pesola, M.; Kähkönen, E.; Ettala, O.; Liimatainen, T.; Pahikkala, T.; Boström, P.; Aronen, H.; Minn, H.; Jambor, I. Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Sci. Rep., 2020, 10(1), 9407.
[http://dx.doi.org/10.1038/s41598-020-66255-8] [PMID: 32523075]
[9]
Boreta, L.; Gadzinski, A.J.; Wu, S.Y.; Xu, M.; Greene, K.; Quanstrom, K.; Nguyen, H.G.; Carroll, P.R.; Hope, T.A.; Feng, F.Y. Location of recurrence by gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology, 2019, 129, 165-171.
[http://dx.doi.org/10.1016/j.urology.2018.12.055] [PMID: 30928607]
[10]
Ceci, F.; Castellucci, P.; Graziani, T.; Farolfi, A.; Fonti, C.; Lodi, F.; Fanti, S. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: Efficacy in different clinical stages of PSA failure after radical therapy. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(1), 31-39.
[http://dx.doi.org/10.1007/s00259-018-4189-7] [PMID: 30350010]
[11]
Tulsyan, S.; Das, C.J.; Tripathi, M.; Seth, A.; Kumar, R.; Bal, C. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl. Med. Commun., 2017, 38(12), 1094-1102.
[http://dx.doi.org/10.1097/MNM.0000000000000749] [PMID: 28957842]
[12]
Hofman, M.S.; Murphy, D.G.; Williams, S.G.; Nzenza, T.; Herschtal, A.; Lourenco, R.A.; Bailey, D.L.; Budd, R.; Hicks, R.J.; Francis, R.J.; Lawrentschuk, N. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): Clinical trial protocol. BJU Int., 2018, 122(5), 783-793.
[http://dx.doi.org/10.1111/bju.14374] [PMID: 29726071]
[13]
Lenzo, N.P.; Meyrick, D.; Turner, J.H. Review of gallium-68 psma pet/ct imaging in the management of prostate cancer. Diagnostics (Basel), 2018, 8(1), 16.
[14]
Bailey, J.; Piert, M. Performance of 68Ga-PSMA PET/CT for Prostate cancer management at initial staging and time of biochemical recurrence. Curr. Urol. Rep., 2017, 18(11), 84.
[http://dx.doi.org/10.1007/s11934-017-0736-1] [PMID: 28889366]
[15]
Parent, E. E.; Schuster, D. M. Update on (18)F-Fluciclovine PET for Prostate Cancer Imaging. J Nucl Med., 2018, 59(5), 733-739.
[http://dx.doi.org/10.2967/jnumed.117.204032] [PMID: 29523631]
[16]
Li, R.; Ravizzini, G.C.; Gorin, M.A.; Maurer, T.; Eiber, M.; Cooperberg, M.R.; Alemozzaffar, M.; Tollefson, M.K.; Delacroix, S.E.; Chapin, B.F. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis., 2018, 21(1), 4-21.
[http://dx.doi.org/10.1038/s41391-017-0007-8] [PMID: 29230009]
[17]
FDA FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer (Accessed on January 1, 2021).
[18]
Markham, A. Relugolix: First Global Approval. Drugs, 2019, 79(6), 675-679.
[http://dx.doi.org/10.1007/s40265-019-01105-0] [PMID: 30937733]
[19]
Shore, N.D.; Saad, F.; Cookson, M.S.; George, D.J.; Saltzstein, D.R.; Tutrone, R.; Akaza, H.; Bossi, A.; van Veenhuyzen, D.F.; Selby, B.; Fan, X.; Kang, V.; Walling, J.; Tombal, B. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl. J. Med., 2020, 382(23), 2187-2196.
[http://dx.doi.org/10.1056/NEJMoa2004325] [PMID: 32469183]
[20]
MacLean, D.B.; Shi, H.; Faessel, H.M.; Saad, F. Medical Castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): Phase 1 study in healthy males. J. Clin. Endocrinol. Metab., 2015, 100(12), 4579-4587.
[http://dx.doi.org/10.1210/jc.2015-2770] [PMID: 26502357]
[21]
FDA FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate- cancer (Accessed on January 1, 2021).
[22]
Walsh, C.S. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol. Oncol., 2015, 137(2), 343-350.
[http://dx.doi.org/10.1016/j.ygyno.2015.02.017] [PMID: 25725131]
[23]
Blackford, A.N.; Jackson, S.P. ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol. Cell, 2017, 66(6), 801-817.
[http://dx.doi.org/10.1016/j.molcel.2017.05.015] [PMID: 28622525]
[24]
Castro, E.; Romero-Laorden, N.; Del Pozo, A.; Lozano, R.; Medina, A.; Puente, J.; Piulats, J.M.; Lorente, D.; Saez, M.I.; Morales-Barrera, R.; Gonzalez-Billalabeitia, E.; Cendón, Y.; García- Carbonero, I.; Borrega, P.; Mendez Vidal, M.J.; Montesa, A.; Nombela, P.; Fernández-Parra, E.; Gonzalez Del Alba, A.; Villa-Guzmán, J.C.; Ibáñez, K.; Rodriguez-Vida, A.; Magraner-Pardo, L.; Perez-Valderrama, B.; Vallespín, E.; Gallardo, E.; Vazquez, S.; Pritchard, C.C.; Lapunzina, P.; Olmos, D. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2019, 37(6), 490-503.
[http://dx.doi.org/10.1200/JCO.18.00358] [PMID: 30625039]
[25]
Na, R.; Zheng, S.L.; Han, M.; Yu, H.; Jiang, D.; Shah, S.; Ewing, C.M.; Zhang, L.; Novakovic, K.; Petkewicz, J.; Gulukota, K.; Helseth, D.L., Jr; Quinn, M.; Humphries, E.; Wiley, K.E.; Isaacs, S.D.; Wu, Y.; Liu, X.; Zhang, N.; Wang, C.H.; Khandekar, J.; Hulick, P.J.; Shevrin, D.H.; Cooney, K.A.; Shen, Z.; Partin, A.W.; Carter, H.B.; Carducci, M.A.; Eisenberger, M.A.; Denmeade, S.R.; McGuire, M.; Walsh, P.C.; Helfand, B.T.; Brendler, C.B.; Ding, Q.; Xu, J.; Isaacs, W.B. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur. Urol., 2017, 71(5), 740-747.
[http://dx.doi.org/10.1016/j.eururo.2016.11.033] [PMID: 27989354]
[26]
Mateo, J.; Porta, N.; Bianchini, D.; McGovern, U.; Elliott, T.; Jones, R.; Syndikus, I.; Ralph, C.; Jain, S.; Varughese, M.; Parikh, O.; Crabb, S.; Robinson, A.; McLaren, D.; Birtle, A.; Tanguay, J.; Miranda, S.; Figueiredo, I.; Seed, G.; Bertan, C.; Flohr, P.; Ebbs, B.; Rescigno, P.; Fowler, G.; Ferreira, A.; Riisnaes, R.; Pereira, R.; Curcean, A.; Chandler, R.; Clarke, M.; Gurel, B.; Crespo, M.; Nava Rodrigues, D.; Sandhu, S.; Espinasse, A.; Chatfield, P.; Tunariu, N.; Yuan, W.; Hall, E.; Carreira, S.; de Bono, J.S. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 2020, 21(1), 162-174.
[http://dx.doi.org/10.1016/S1470-2045(19)30684-9] [PMID: 31806540]
[27]
Mateo, J.; Carreira, S.; Sandhu, S.; Miranda, S.; Mossop, H.; Perez-Lopez, R.; Nava Rodrigues, D.; Robinson, D.; Omlin, A.; Tunariu, N.; Boysen, G.; Porta, N.; Flohr, P.; Gillman, A.; Figueiredo, I.; Paulding, C.; Seed, G.; Jain, S.; Ralph, C.; Protheroe, A.; Hussain, S.; Jones, R.; Elliott, T.; McGovern, U.; Bianchini, D.; Goodall, J.; Zafeiriou, Z.; Williamson, C.T.; Ferraldeschi, R.; Riisnaes, R.; Ebbs, B.; Fowler, G.; Roda, D.; Yuan, W.; Wu, Y.M.; Cao, X.; Brough, R.; Pemberton, H.; A’Hern, R.; Swain, A.; Kunju, L.P.; Eeles, R.; Attard, G.; Lord, C.J.; Ashworth, A.; Rubin, M.A.; Knudsen, K.E.; Feng, F.Y.; Chinnaiyan, A.M.; Hall, E.; de Bono, J.S. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med., 2015, 373(18), 1697-1708.
[http://dx.doi.org/10.1056/NEJMoa1506859] [PMID: 26510020]
[28]
Robson, M.; Im, S-A.; Senkus, E.; Binghe, Xu.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; Runswick, S.; Conte, P.; Flohr, P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med., 2017, 377(17), 1700.
[http://dx.doi.org/10.1056/NEJMx170012] [PMID: 28792849]
[29]
O’Connor, M.J. Targeting the DNA damage response in cancer. Mol. Cell, 2015, 60(4), 547-560.
[http://dx.doi.org/10.1016/j.molcel.2015.10.040] [PMID: 26590714]
[30]
Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
[http://dx.doi.org/10.1056/NEJMoa0900212] [PMID: 19553641]
[31]
Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmaña, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; Hubert, A.; Rosengarten, O.; Steiner, M.; Loman, N.; Bowen, K.; Fielding, A.; Domchek, S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol., 2015, 33(3), 244-250.
[http://dx.doi.org/10.1200/JCO.2014.56.2728] [PMID: 25366685]
[32]
Nizialek, E.; Antonarakis, E.S. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag. Res., 2020, 12, 8105-8114.
[http://dx.doi.org/10.2147/CMAR.S227033] [PMID: 32982407]
[33]
de Bono, J.; Mateo, J.; Fizazi, K.; Saad, F.; Shore, N.; Sandhu, S.; Chi, K.N.; Sartor, O.; Agarwal, N.; Olmos, D.; Thiery-Vuillemin, A.; Twardowski, P.; Mehra, N.; Goessl, C.; Kang, J.; Burgents, J.; Wu, W.; Kohlmann, A.; Adelman, C.A.; Hussain, M. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med., 2020, 382(22), 2091-2102.
[http://dx.doi.org/10.1056/NEJMoa1911440] [PMID: 32343890]
[34]
Hussain, M.; Mateo, J.; Fizazi, K.; Saad, F.; Shore, N.; Sandhu, S.; Chi, K.N.; Sartor, O.; Agarwal, N.; Olmos, D.; Thiery-Vuillemin, A.; Twardowski, P.; Roubaud, G.; Özgüroğlu, M.; Kang, J.; Burgents, J.; Gresty, C.; Corcoran, C.; Adelman, C.A.; de Bono, J. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med., 2020, 383(24), 2345-2357.
[http://dx.doi.org/10.1056/NEJMoa2022485] [PMID: 32955174]
[35]
Goodall, J.; Mateo, J.; Yuan, W.; Mossop, H.; Porta, N.; Miranda, S.; Perez-Lopez, R.; Dolling, D.; Robinson, D.R.; Sandhu, S.; Fowler, G.; Ebbs, B.; Flohr, P.; Seed, G.; Rodrigues, D.N.; Boysen, G.; Bertan, C.; Atkin, M.; Clarke, M.; Crespo, M.; Figueiredo, I.; Riisnaes, R.; Sumanasuriya, S.; Rescigno, P.; Zafeiriou, Z.; Sharp, A.; Tunariu, N.; Bianchini, D.; Gillman, A.; Lord, C.J.; Hall, E.; Chinnaiyan, A.M.; Carreira, S.; de Bono, J.S. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov., 2017, 7(9), 1006-1017.
[http://dx.doi.org/10.1158/2159-8290.CD-17-0261] [PMID: 28450425]
[36]
Karzai, F.; VanderWeele, D.; Madan, R.A.; Owens, H.; Cordes, L.M.; Hankin, A.; Couvillon, A.; Nichols, E.; Bilusic, M.; Beshiri, M.L.; Kelly, K.; Krishnasamy, V.; Lee, S.; Lee, M.J.; Yuno, A.; Trepel, J.B.; Merino, M.J.; Dittamore, R.; Marté, J.; Donahue, R.N.; Schlom, J.; Killian, K.J.; Meltzer, P.S.; Steinberg, S.M.; Gulley, J.L.; Lee, J.M.; Dahut, W.L. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer, 2018, 6(1), 141.
[http://dx.doi.org/10.1186/s40425-018-0463-2] [PMID: 30514390]
[37]
Clarke, N.; Wiechno, P.; Alekseev, B.; Sala, N.; Jones, R.; Kocak, I.; Chiuri, V.E.; Jassem, J.; Fléchon, A.; Redfern, C.; Goessl, C.; Burgents, J.; Kozarski, R.; Hodgson, D.; Learoyd, M.; Saad, F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 2018, 19(7), 975-986.
[http://dx.doi.org/10.1016/S1470-2045(18)30365-6] [PMID: 29880291]
[38]
Perez-Lopez, R.; Mateo, J.; Mossop, H.; Blackledge, M.D.; Collins, D.J.; Rata, M.; Morgan, V.A.; Macdonald, A.; Sandhu, S.; Lorente, D.; Rescigno, P.; Zafeiriou, Z.; Bianchini, D.; Porta, N.; Hall, E.; Leach, M.O.; de Bono, J.S.; Koh, D.M.; Tunariu, N. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283(1), 168-177.
[http://dx.doi.org/10.1148/radiol.2016160646] [PMID: 27875103]
[40]
Abida, W.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A.H.; McDermott, R.; Sautois, B.; Vogelzang, N.J.; Bambury, R.M.; Voog, E.; Zhang, J.; Piulats, J.M.; Ryan, C.J.; Merseburger, A.S.; Daugaard, G.; Heidenreich, A.; Fizazi, K.; Higano, C.S.; Krieger, L.E.; Sternberg, C.N.; Watkins, S.P.; Despain, D.; Simmons, A.D.; Loehr, A.; Dowson, M.; Golsorkhi, T.; Chowdhury, S. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol., 2020, 38(32), 3763-3772.
[http://dx.doi.org/10.1200/JCO.20.01035] [PMID: 32795228]
[41]
Abida, W.; Campbell, D.; Patnaik, A.; Shapiro, J. D.; Sautois, B.; Vogelzang, N.J.; Voog, E.G.; Bryce, A.H.; McDermott, R.; Ricci, F.; Rowe, J.; Zhang, J.; Piulats, J.M.; Fizazi, K.; Merseburger, A.S.; Higano, C.S.; Krieger, L.E.; Ryan, C.J.; Feng, F.Y.; Simmons, A.D.; Loehr, A.; Despain, D.; Dowson, M.; Green, F.; Watkins, S.P.; Golsorkhi, T.; Chowdhury, S. Non-BRCA DNA damage repair gene alterations and response to the parp inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin. Cancer Res., 2020, 26(11), 2487-2496.
[42]
Sokolova, A. O.; Yu, E. Y.; Cheng, H. H. Honing in on PARPi response in prostate cancer: from HR pathway to gene-by-gene granularity. Clin. Cancer Res., 2020, 26(11), 2439-2440.
[43]
Fizazi, K.; Shore, N.; Tammela, T.L.; Ulys, A.; Vjaters, E.; Polyakov, S.; Jievaltas, M.; Luz, M.; Alekseev, B.; Kuss, I.; Kappeler, C.; Snapir, A.; Sarapohja, T.; Smith, M.R. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med., 2019, 380(13), 1235-1246.
[http://dx.doi.org/10.1056/NEJMoa1815671] [PMID: 30763142]
[44]
Fizazi, K.; Shore, N.; Tammela, T.L.; Ulys, A.; Vjaters, E.; Polyakov, S.; Jievaltas, M.; Luz, M.; Alekseev, B.; Kuss, I.; Le Berre, M.A.; Petrenciuc, O.; Snapir, A.; Sarapohja, T.; Smith, M.R. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl. J. Med., 2020, 383(11), 1040-1049.
[http://dx.doi.org/10.1056/NEJMoa2001342] [PMID: 32905676]
[45]
Matsubara, N.; Mukai, H.; Hosono, A.; Onomura, M.; Sasaki, M.; Yajima, Y.; Hashizume, K.; Yasuda, M.; Uemura, M.; Zurth, C. Phase 1 study of darolutamide (ODM-201): A new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother. Pharmacol., 2017, 80(6), 1063-1072.
[http://dx.doi.org/10.1007/s00280-017-3417-3] [PMID: 28801852]
[46]
Shore, N.; Zurth, C.; Fricke, R.; Gieschen, H.; Graudenz, K.; Koskinen, M.; Ploeger, B.; Moss, J.; Prien, O.; Borghesi, G.; Petrenciuc, O.; Tammela, T.L.; Kuss, I.; Verholen, F.; Smith, M.R.; Fizazi, K. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target. Oncol., 2019, 14(5), 527-539.
[http://dx.doi.org/10.1007/s11523-019-00674-0] [PMID: 31571095]
[47]
Zurth, C.; Koskinen, M.; Fricke, R.; Prien, O.; Korjamo, T.; Graudenz, K.; Denner, K.; Bairlein, M.; von Bühler, C.J.; Wilkinson, G.; Gieschen, H. Drug-drug interaction potential of darolutamide: In vitro and clinical studies. Eur. J. Drug Metab. Pharmacokinet., 2019, 44(6), 747-759.
[http://dx.doi.org/10.1007/s13318-019-00577-5] [PMID: 31571146]
[48]
FDA FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-type-prostate-cancer-using-novel- clinical-trial-endpoint (Accessed January 1, 2021).
[49]
FDA FDA approves apalutamide for metastatic castration-sensitive prostate cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer (Accessed January 1, 2021).
[50]
Smith, M.R.; Saad, F.; Chowdhury, S.; Oudard, S.; Hadaschik, B.A.; Graff, J.N.; Olmos, D.; Mainwaring, P.N.; Lee, J.Y.; Uemura, H.; Lopez-Gitlitz, A.; Trudel, G.C.; Espina, B.M.; Shu, Y.; Park, Y.C.; Rackoff, W.R.; Yu, M.K.; Small, E.J. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med., 2018, 378(15), 1408-1418.
[http://dx.doi.org/10.1056/NEJMoa1715546] [PMID: 29420164]
[51]
Small, E.J.; Saad, F.; Chowdhury, S.; Oudard, S.; Hadaschik, B.A.; Graff, J.N.; Olmos, D.; Mainwaring, P.N.; Lee, J.Y.; Uemura, H.; De Porre, P.; Smith, A.A.; Zhang, K.; Lopez-Gitlitz, A.; Smith, M.R. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann. Oncol., 2019, 30(11), 1813-1820.
[http://dx.doi.org/10.1093/annonc/mdz397] [PMID: 31560066]
[52]
Smith, M.R.; Antonarakis, E.S.; Ryan, C.J.; Berry, W.R.; Shore, N.D.; Liu, G.; Alumkal, J.J.; Higano, C.S.; Chow Maneval, E.; Bandekar, R.; de Boer, C.J.; Yu, M.K.; Rathkopf, D.E. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur. Urol., 2016, 70(6), 963-970.
[http://dx.doi.org/10.1016/j.eururo.2016.04.023] [PMID: 27160947]
[53]
Chi, K.N.; Agarwal, N.; Bjartell, A.; Chung, B.H.; Pereira de Santana Gomes, A.J.; Given, R.; Juárez Soto, Á.; Merseburger, A.S.; Özgüroğlu, M.; Uemura, H.; Ye, D.; Deprince, K.; Naini, V.; Li, J.; Cheng, S.; Yu, M.K.; Zhang, K.; Larsen, J.S.; McCarthy, S.; Chowdhury, S. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med., 2019, 381(1), 13-24.
[http://dx.doi.org/10.1056/NEJMoa1903307] [PMID: 31150574]
[54]
Agarwal, N.; McQuarrie, K.; Bjartell, A.; Chowdhury, S.; Pereira de Santana Gomes, A.J.; Chung, B.H.; Özgüroğlu, M.; Juárez Soto, Á.; Merseburger, A.S.; Uemura, H.; Ye, D.; Given, R.; Cella, D.; Basch, E.; Miladinovic, B.; Dearden, L.; Deprince, K.; Naini, V.; Lopez-Gitlitz, A.; Chi, K.N. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2019, 20(11), 1518-1530.
[http://dx.doi.org/10.1016/S1470-2045(19)30620-5] [PMID: 31578173]
[55]
Rathkopf, D.E.; Antonarakis, E.S.; Shore, N.D.; Tutrone, R.F.; Alumkal, J.J.; Ryan, C.J.; Saleh, M.; Hauke, R.J.; Bandekar, R.; Maneval, E.C.; de Boer, C.J.; Yu, M.K.; Scher, H.I. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin. Cancer Res., 2017, 23(14), 3544-3551.
[56]
Tsuchiya, T.; Imanaka, K.; Iwaki, Y.; Oyama, R.; Hashine, K.; Yamaguchi, A.; Uemura, H. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer. Int. J. Clin. Oncol., 2019, 24(12), 1596-1604.
[http://dx.doi.org/10.1007/s10147-019-01526-7] [PMID: 31446511]
[57]
FDA FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cance. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive#:~:text=On%20February%207%2C%202018%2C%20the,sensitive%20prostate%20cancer%20(CSPC) (Accessed January 1, 2021).
[58]
Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev, B.Y.; Özgüroğlu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; De Porre, P.; Kheoh, T.; Park, Y.C.; Todd, M.B.; Chi, K.N. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med., 2017, 377(4), 352-360.
[http://dx.doi.org/10.1056/NEJMoa1704174] [PMID: 28578607]
[59]
Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev, B.Y.; Özgüroğlu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; Sulur, G.; Luna, Y.; Li, S.; Mundle, S.; Chi, K.N. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol., 2019, 20(5), 686-700.
[http://dx.doi.org/10.1016/S1470-2045(19)30082-8] [PMID: 30987939]
[60]
Fukasawa, S.; Suzuki, H.; Kawaguchi, K.; Noguchi, H.; Enjo, K.; Tran, N.; Todd, M.; Fizazi, K.; Matsubara, N. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: A subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn. J. Clin. Oncol., 2018, 48(11), 1012-1021.
[http://dx.doi.org/10.1093/jjco/hyy129] [PMID: 30371895]
[61]
Tsao, C.K.; Sfakianos, J.; Liaw, B.; Gimpel-Tetra, K.; Kemeny, M.; Bulone, L.; Shahin, M.; Oh, W.K.; Galsky, M.D.; Phase, I.I. Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer. Oncologist, 2016, 21(12), e1414-e1419.
[http://dx.doi.org/10.1634/theoncologist.2016-0026] [PMID: 27742908]
[62]
James, N.D.; de Bono, J.S.; Spears, M.R.; Clarke, N.W.; Mason, M.D.; Dearnaley, D.P.; Ritchie, A.W.S.; Amos, C.L.; Gilson, C.; Jones, R.J.; Matheson, D.; Millman, R.; Attard, G.; Chowdhury, S.; Cross, W.R.; Gillessen, S.; Parker, C.C.; Russell, J.M.; Berthold, D.R.; Brawley, C.; Adab, F.; Aung, S.; Birtle, A.J.; Bowen, J.; Brock, S.; Chakraborti, P.; Ferguson, C.; Gale, J.; Gray, E.; Hingorani, M.; Hoskin, P.J.; Lester, J.F.; Malik, Z.I.; McKinna, F.; McPhail, N.; Money-Kyrle, J.; O’Sullivan, J.; Parikh, O.; Protheroe, A.; Robinson, A.; Srihari, N.N.; Thomas, C.; Wagstaff, J.; Wylie, J.; Zarkar, A.; Parmar, M.K.B.; Sydes, M.R. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med., 2017, 377(4), 338-351.
[http://dx.doi.org/10.1056/NEJMoa1702900] [PMID: 28578639]
[63]
Chi, K.N.; Protheroe, A.; Rodríguez-Antolín, A.; Facchini, G.; Suttman, H.; Matsubara, N.; Ye, Z.; Keam, B.; Damião, R.; Li, T.; McQuarrie, K.; Jia, B.; De Porre, P.; Martin, J.; Todd, M.B.; Fizazi, K. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. Lancet Oncol., 2018, 19(2), 194-206.
[http://dx.doi.org/10.1016/S1470-2045(17)30911-7] [PMID: 29326030]
[64]
Rathkopf, D.E.; Smith, M.R.; de Bono, J.S.; Logothetis, C.J.; Shore, N.D.; de Souza, P.; Fizazi, K.; Mulders, P.F.; Mainwaring, P.; Hainsworth, J.D.; Beer, T.M.; North, S.; Fradet, Y.; Van Poppel, H.; Carles, J.; Flaig, T.W.; Efstathiou, E.; Yu, E.Y.; Higano, C.S.; Taplin, M.E.; Griffin, T.W.; Todd, M.B.; Yu, M.K.; Park, Y.C.; Kheoh, T.; Small, E.J.; Scher, H.I.; Molina, A.; Ryan, C.J.; Saad, F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol., 2014, 66(5), 815-825.
[http://dx.doi.org/10.1016/j.eururo.2014.02.056] [PMID: 24647231]
[65]
Fizazi, K.; Scher, H.I.; Molina, A.; Logothetis, C.J.; Chi, K.N.; Jones, R.J.; Staffurth, J.N.; North, S.; Vogelzang, N.J.; Saad, F.; Mainwaring, P.; Harland, S.; Goodman, O.B., Jr; Sternberg, C.N.; Li, J.H.; Kheoh, T.; Haqq, C.M.; de Bono, J.S. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 2012, 13(10), 983-992.
[http://dx.doi.org/10.1016/S1470-2045(12)70379-0] [PMID: 22995653]
[66]
Ryan, C.J.; Smith, M.R.; Fizazi, K.; Saad, F.; Mulders, P.F.; Sternberg, C.N.; Miller, K.; Logothetis, C.J.; Shore, N.D.; Small, E.J.; Carles, J.; Flaig, T.W.; Taplin, M.E.; Higano, C.S.; de Souza, P.; de Bono, J.S.; Griffin, T.W.; De Porre, P.; Yu, M.K.; Park, Y.C.; Li, J.; Kheoh, T.; Naini, V.; Molina, A.; Rathkopf, D.E. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 2015, 16(2), 152-160.
[http://dx.doi.org/10.1016/S1470-2045(14)71205-7] [PMID: 25601341]
[67]
Miller, K.; Carles, J.; Gschwend, J.E.; Van Poppel, H.; Diels, J.; Brookman-May, S.D. The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: Stratified analysis based on pain, prostate-specific antigen, and gleason score. Eur. Urol., 2018, 74(1), 17-23.
[http://dx.doi.org/10.1016/j.eururo.2017.08.035] [PMID: 28939004]
[68]
Stein, C.A.; Levin, R.; Given, R.; Higano, C.S.; Nemeth, P.; Bosch, B.; Chapas-Reed, J.; Dreicer, R. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs.. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. Urol. Oncol., 2018, 36(2), 81.e9-81.e16.
[http://dx.doi.org/10.1016/j.urolonc.2017.10.018] [PMID: 29150328]
[69]
Smith, M.R.; Rathkopf, D.E.; Mulders, P.F.; Carles, J.; Van Poppel, H.; Li, J.; Kheoh, T.; Griffin, T.W.; Molina, A.; Ryan, C.J. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naïve patients with metastatic castration resistant Prostate cancer. J. Urol., 2015, 194(5), 1277-1284.
[http://dx.doi.org/10.1016/j.juro.2015.07.004] [PMID: 26151676]
[70]
de Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr; Saad, F.; Staffurth, J.N.; Mainwaring, P.; Harland, S.; Flaig, T.W.; Hutson, T.E.; Cheng, T.; Patterson, H.; Hainsworth, J.D.; Ryan, C.J.; Sternberg, C.N.; Ellard, S.L.; Fléchon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C.M.; Scher, H.I. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 2011, 364(21), 1995-2005.
[http://dx.doi.org/10.1056/NEJMoa1014618] [PMID: 21612468]
[71]
Ryan, C.J.; Smith, M.R.; de Bono, J.S.; Molina, A.; Logothetis, C.J.; de Souza, P.; Fizazi, K.; Mainwaring, P.; Piulats, J.M.; Ng, S.; Carles, J.; Mulders, P.F.; Basch, E.; Small, E.J.; Saad, F.; Schrijvers, D.; Van Poppel, H.; Mukherjee, S.D.; Suttmann, H.; Gerritsen, W.R.; Flaig, T.W.; George, D.J.; Yu, E.Y.; Efstathiou, E.; Pantuck, A.; Winquist, E.; Higano, C.S.; Taplin, M.E.; Park, Y.; Kheoh, T.; Griffin, T.; Scher, H.I.; Rathkopf, D.E. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 2013, 368(2), 138-148.
[http://dx.doi.org/10.1056/NEJMoa1209096] [PMID: 23228172]
[72]
Attard, G.; Reid, A.H.; Yap, T.A.; Raynaud, F.; Dowsett, M.; Settatree, S.; Barrett, M.; Parker, C.; Martins, V.; Folkerd, E.; Clark, J.; Cooper, C.S.; Kaye, S.B.; Dearnaley, D.; Lee, G.; de Bono, J.S. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol., 2008, 26(28), 4563-4571.
[http://dx.doi.org/10.1200/JCO.2007.15.9749] [PMID: 18645193]
[73]
Attard, G.; Reid, A.H.; A’Hern, R.; Parker, C.; Oommen, N.B.; Folkerd, E.; Messiou, C.; Molife, L.R.; Maier, G.; Thompson, E.; Olmos, D.; Sinha, R.; Lee, G.; Dowsett, M.; Kaye, S.B.; Dearnaley, D.; Kheoh, T.; Molina, A.; de Bono, J.S. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol., 2009, 27(23), 3742-3748.
[http://dx.doi.org/10.1200/JCO.2008.20.0642] [PMID: 19470933]
[74]
Tannock, I.; Gospodarowicz, M.; Meakin, W.; Panzarella, T.; Stewart, L.; Rider, W. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol., 1989, 7(5), 590-597.
[http://dx.doi.org/10.1200/JCO.1989.7.5.590] [PMID: 2709088]
[75]
Arora, V.K.; Schenkein, E.; Murali, R.; Subudhi, S.K.; Wongvipat, J.; Balbas, M.D.; Shah, N.; Cai, L.; Efstathiou, E.; Logothetis, C.; Zheng, D.; Sawyers, C.L. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 2013, 155(6), 1309-1322.
[http://dx.doi.org/10.1016/j.cell.2013.11.012] [PMID: 24315100]
[76]
Richards, J.; Lim, A.C.; Hay, C.W.; Taylor, A.E.; Wingate, A.; Nowakowska, K.; Pezaro, C.; Carreira, S.; Goodall, J.; Arlt, W.; McEwan, I.J.; de Bono, J.S.; Attard, G. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res., 2012, 72(9), 2176-2182.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3980] [PMID: 22411952]
[77]
McKay, R.R.; Werner, L.; Jacobus, S.J.; Jones, A.; Mostaghel, E.A.; Marck, B.T.; Choudhury, A.D.; Pomerantz, M.M.; Sweeney, C.J.; Slovin, S.F.; Morris, M.J.; Kantoff, P.W.; Taplin, M.E. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer, 2019, 125(4), 524-532.
[http://dx.doi.org/10.1002/cncr.31836] [PMID: 30427533]
[78]
Cindolo, L.; Natoli, C.; De Nunzio, C.; De Tursi, M.; Valeriani, M.; Giacinti, S.; Micali, S.; Rizzo, M.; Bianchi, G.; Martorana, E.; Scarcia, M.; Ludovico, G.M.; Bove, P.; Laudisi, A.; Selvaggio, O.; Carrieri, G.; Bada, M.; Castellan, P.; Topazio, L.; Boccasile, S.; Ditonno, P.; Chiodini, P.; Schips, L. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer in chemotherapy-naive patients: An italian analysis of patients’ satisfaction. Clin. Genitourin. Cancer, 2017, 15(5), 520-525.
[http://dx.doi.org/10.1016/j.clgc.2017.04.003] [PMID: 28478884]
[79]
Yildirim, B. A.; Onal, C.; Kose, F.; Oymak, E.; Sedef, A. M.; Besen, A. A.; Aksoy, S.; Guler, O. C.; Sumbul, A. T.; Muallaoglu, S.; Mertsoylu, H.; Ozyigit, G. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Strahlenther. Onkol., 2019, 195(10), 872-881.
[80]
Cindolo, L.; Natoli, C.; De Nunzio, C.; De Tursi, M.; Valeriani, M.; Giacinti, S.; Micali, S.; Rizzo, M.; Bianchi, G.; Martorana, E.; Scarcia, M.; Ludovico, G.M.; Bove, P.; Laudisi, A.; Selvaggio, O.; Carrieri, G.; Bada, M.; Castellan, P.; Boccasile, S.; Ditonno, P.; Chiodini, P.; Verze, P.; Mirone, V.; Schips, L. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study. BMC Cancer, 2017, 17(1), 753.
[http://dx.doi.org/10.1186/s12885-017-3755-x] [PMID: 29126389]
[81]
Szmulewitz, R.Z.; Peer, C.J.; Ibraheem, A.; Martinez, E.; Kozloff, M.F.; Carthon, B.; Harvey, R.D.; Fishkin, P.; Yong, W.P.; Chiong, E.; Nabhan, C.; Karrison, T.; Figg, W.D.; Stadler, W.M.; Ratain, M.J. Prospective international randomized phase ii study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J. Clin. Oncol., 2018, 36(14), 1389-1395.
[http://dx.doi.org/10.1200/JCO.2017.76.4381] [PMID: 29590007]
[82]
Taplin, M.E.; Montgomery, B.; Logothetis, C.J.; Bubley, G.J.; Richie, J.P.; Dalkin, B.L.; Sanda, M.G.; Davis, J.W.; Loda, M.; True, L.D.; Troncoso, P.; Ye, H.; Lis, R.T.; Marck, B.T.; Matsumoto, A.M.; Balk, S.P.; Mostaghel, E.A.; Penning, T.M.; Nelson, P.S.; Xie, W.; Jiang, Z.; Haqq, C.M.; Tamae, D.; Tran, N.; Peng, W.; Kheoh, T.; Molina, A.; Kantoff, P.W. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study. J. Clin. Oncol., 2014, 32(33), 3705-3715.
[http://dx.doi.org/10.1200/JCO.2013.53.4578] [PMID: 25311217]
[83]
Friedlander, T.W.; Graff, J.N.; Zejnullahu, K.; Anantharaman, A.; Zhang, L.; Paz, R.; Premasekharan, G.; Russell, C.; Huang, Y.; Kim, W.; Aggarwal, R.R.; Lin, A.M.; Fong, L.; Alumkal, J.J.; Beer, T.M.; Sharifi, N.; Alyamani, M.; Dittamore, R.; Small, E.J.; Paris, P.L.; Ryan, C.J. High-dose abiraterone acetate in men with castration resistant prostate cancer. Clin. Genitourin. Cancer, 2017, 15(6), 733-741.e1.
[http://dx.doi.org/10.1016/j.clgc.2017.05.026] [PMID: 28655452]
[84]
Tagawa, S.T.; Posadas, E.M.; Bruce, J.; Lim, E.A.; Petrylak, D.P.; Peng, W.; Kheoh, T.; Maul, S.; Smit, J.W.; Gonzalez, M.D.; De Porre, P.; Tran, N.; Nanus, D.M. Phase 1b study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur. Urol., 2016, 70(5), 718-721.
[http://dx.doi.org/10.1016/j.eururo.2016.01.028] [PMID: 26852075]
[85]
Kwak, C.; Wu, T.T.; Lee, H.M.; Wu, H.C.; Hong, S.J.; Ou, Y.C.; Byun, S.S.; Rhim, H.Y.; Kheoh, T.; Wan, Y.; Yeh, H.; Yu, M.K.; Kim, C.S. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients. Int. J. Urol., 2014, 21(12), 1239-1244.
[86]
Sun, Y.; Zou, Q.; Sun, Z.; Li, C.; Du, C.; Chen, Z.; Shan, Y.; Huang, Y.; Jin, J.; Ye, Z. Q.; Xie, L.; Lin, G.; Feng, Y.; De Porre, P.; Liu, W.; Ye, D. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Int. J. Urol., 2016, 23(5), 404-411.
[87]
Reid, A.H.; Attard, G.; Danila, D.C.; Oommen, N.B.; Olmos, D.; Fong, P.C.; Molife, L.R.; Hunt, J.; Messiou, C.; Parker, C.; Dearnaley, D.; Swennenhuis, J.F.; Terstappen, L.W.; Lee, G.; Kheoh, T.; Molina, A.; Ryan, C.J.; Small, E.; Scher, H.I.; de Bono, J.S. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol., 2010, 28(9), 1489-1495.
[http://dx.doi.org/10.1200/JCO.2009.24.6819] [PMID: 20159823]
[88]
Danila, D.C.; Morris, M.J.; de Bono, J.S.; Ryan, C.J.; Denmeade, S.R.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Kheoh, T.; Haqq, C.; Molina, A.; Anand, A.; Koscuiszka, M.; Larson, S.M.; Schwartz, L.H.; Fleisher, M.; Scher, H.I. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol., 2010, 28(9), 1496-1501.
[http://dx.doi.org/10.1200/JCO.2009.25.9259] [PMID: 20159814]
[90]
Armstrong, A.J.; Szmulewitz, R.Z.; Petrylak, D.P.; Holzbeierlein, J.; Villers, A.; Azad, A.; Alcaraz, A.; Alekseev, B.; Iguchi, T.; Shore, N.D.; Rosbrook, B.; Sugg, J.; Baron, B.; Chen, L.; Stenzl, A. ARCHES: A randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol., 2019, 37(32), 2974-2986.
[http://dx.doi.org/10.1200/JCO.19.00799] [PMID: 31329516]
[91]
Penson, D.F.; Armstrong, A.J.; Concepcion, R.; Agarwal, N.; Olsson, C.; Karsh, L.; Dunshee, C.; Wang, F.; Wu, K.; Krivoshik, A.; Phung, D.; Higano, C.S. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial. J. Clin. Oncol., 2016, 34(18), 2098-2106.
[http://dx.doi.org/10.1200/JCO.2015.64.9285] [PMID: 26811535]
[92]
Shore, N.D.; Chowdhury, S.; Villers, A.; Klotz, L.; Siemens, D.R.; Phung, D.; van Os, S.; Hasabou, N.; Wang, F.; Bhattacharya, S.; Heidenreich, A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): A randomised, double-blind, phase 2 study. Lancet Oncol., 2016, 17(2), 153-163.
[http://dx.doi.org/10.1016/S1470-2045(15)00518-5] [PMID: 26774508]
[93]
Iguchi, T.; Tamada, S.; Kato, M.; Yasuda, S.; Machida, Y.; Ohmachi, T.; Ishii, K.; Iwata, H.; Yamamoto, S.; Kanamaru, T.; Morimoto, K.; Hase, T.; Tashiro, K.; Harimoto, K.; Deguchi, T.; Adachi, T.; Iwamoto, K.; Takegaki, Y.; Nakatani, T. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: The OCUU-CRPC study. Int. J. Clin. Oncol., 2020, 25(3), 486-494.
[http://dx.doi.org/10.1007/s10147-019-01554-3] [PMID: 31564004]
[94]
Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; Davis, I.D.; de Bono, J.S.; Evans, C.P.; Fizazi, K.; Joshua, A.M.; Kim, C.S.; Kimura, G.; Mainwaring, P.; Mansbach, H.; Miller, K.; Noonberg, S.B.; Perabo, F.; Phung, D.; Saad, F.; Scher, H.I.; Taplin, M.E.; Venner, P.M.; Tombal, B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 2014, 371(5), 424-433.
[http://dx.doi.org/10.1056/NEJMoa1405095] [PMID: 24881730]
[95]
Loriot, Y.; Miller, K.; Sternberg, C.N.; Fizazi, K.; De Bono, J.S.; Chowdhury, S.; Higano, C.S.; Noonberg, S.; Holmstrom, S.; Mansbach, H.; Perabo, F.G.; Phung, D.; Ivanescu, C.; Skaltsa, K.; Beer, T.M.; Tombal, B. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncol., 2015, 16(5), 509-521.
[http://dx.doi.org/10.1016/S1470-2045(15)70113-0] [PMID: 25888263]
[96]
Evans, C.P.; Higano, C.S.; Keane, T.; Andriole, G.; Saad, F.; Iversen, P.; Miller, K.; Kim, C.S.; Kimura, G.; Armstrong, A.J.; Sternberg, C.N.; Loriot, Y.; de Bono, J.; Noonberg, S.B.; Mansbach, H.; Bhattacharya, S.; Perabo, F.; Beer, T.M.; Tombal, B. The prevail study: Primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy- naïve metastatic castration-resistant prostate cancer. Eur. Urol., 2016, 70(4), 675-683.
[http://dx.doi.org/10.1016/j.eururo.2016.03.017] [PMID: 27006332]
[97]
Armstrong, A.J.; Lin, P.; Higano, C.S.; Iversen, P.; Sternberg, C.N.; Tombal, B.; Phung, D.; Parli, T.; Krivoshik, A.; Beer, T.M. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur. Urol. Oncol., 2019, 2(6), 677-684.
[98]
Davis, I.D.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.; Pook, D.W.; Reaume, M.N.; Sandhu, S.K.; Tan, A.; Tan, T.H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S.G.; Yip, S.; Zhang, A.Y.; Zielinski, R.R.; Sweeney, C.J. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med., 2019, 381(2), 121-131.
[http://dx.doi.org/10.1056/NEJMoa1903835] [PMID: 31157964]
[99]
Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; Armstrong, A.J.; Flaig, T.W.; Fléchon, A.; Mainwaring, P.; Fleming, M.; Hainsworth, J.D.; Hirmand, M.; Selby, B.; Seely, L.; de Bono, J.S. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367(13), 1187-1197.
[http://dx.doi.org/10.1056/NEJMoa1207506] [PMID: 22894553]
[100]
Loriot, Y.; Fizazi, K.; de Bono, J.S.; Forer, D.; Hirmand, M.; Scher, H.I. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer, 2017, 123(2), 253-262.
[http://dx.doi.org/10.1002/cncr.30336] [PMID: 27648814]
[101]
Graff, J.N.; Alumkal, J.J.; Drake, C.G.; Thomas, G.V.; Redmond, W.L.; Farhad, M.; Cetnar, J.P.; Ey, F.S.; Bergan, R.C.; Slottke, R.; Beer, T.M. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget, 2016, 7(33), 52810-52817.
[http://dx.doi.org/10.18632/oncotarget.10547] [PMID: 27429197]
[102]
Gibbons, J.A.; Ouatas, T.; Krauwinkel, W.; Ohtsu, Y.; van der Walt, J.S.; Beddo, V.; de Vries, M.; Mordenti, J. Clinical pharmacokinetic studies of enzalutamide. Clin. Pharmacokinet., 2015, 54(10), 1043-1055.
[http://dx.doi.org/10.1007/s40262-015-0271-5] [PMID: 25917876]
[103]
Liu, Y.M.; Wu, P.; Fukushi, R.; Yamada, S.; Chen, Q. Pharmacokinetics and safety of enzalutamide in healthy chinese male volunteers. Clin. Ther., 2019, 41(2), 261-268.
[http://dx.doi.org/10.1016/j.clinthera.2018.12.002] [PMID: 30642613]
[104]
Gibbons, J.A.; de Vries, M.; Krauwinkel, W.; Ohtsu, Y.; Noukens, J.; van der Walt, J.S.; Mol, R.; Mordenti, J.; Ouatas, T. Pharmacokinetic drug interaction studies with enzalutamide. Clin. Pharmacokinet., 2015, 54(10), 1057-1069.
[http://dx.doi.org/10.1007/s40262-015-0283-1] [PMID: 25929560]
[105]
de Bono, J.S.; Chowdhury, S.; Feyerabend, S.; Elliott, T.; Grande, E.; Melhem-Bertrandt, A.; Baron, B.; Hirmand, M.; Werbrouck, P.; Fizazi, K. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in europe. Eur. Urol., 2018, 74(1), 37-45.
[http://dx.doi.org/10.1016/j.eururo.2017.07.035] [PMID: 28844372]
[106]
Attard, G.; Borre, M.; Gurney, H.; Loriot, Y.; Andresen-Daniil, C.; Kalleda, R.; Pham, T.; Taplin, M.E. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol., 2018, 36(25), 2639-2646.
[http://dx.doi.org/10.1200/JCO.2018.77.9827] [PMID: 30028657]
[107]
Shore, N.D.; Saltzstein, D.; Sieber, P.; Mehlhaff, B.; Gervasi, L.; Phillips, J.; Wong, Y.N.; Pei, H.; McGowan, T. Results of a real- world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clin. Genitourin. Cancer, 2019, 17(6), 457-463.e6.
[http://dx.doi.org/10.1016/j.clgc.2019.07.017] [PMID: 31473120]
[108]
Krauwinkel, W.; Noukens, J.; van Dijk, J.; Popa, S.; Ouatas, T.; de Vries, M.; Phung, D.; Gibbons, J.; Mordenti, J.; Mateva, L. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. J. Clin. Pharm. Ther., 2017, 42(3), 268-275.
[http://dx.doi.org/10.1111/jcpt.12503] [PMID: 28251667]
[109]
Abbaspour Babaei, M.; Kamalidehghan, B.; Saleem, M.; Huri, H.Z.; Ahmadipour, F. Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells. Drug Des. Devel. Ther., 2016, 10, 2443-2459.
[http://dx.doi.org/10.2147/DDDT.S89114] [PMID: 27536065]
[110]
Swami, U.; McFarland, T.R.; Nussenzveig, R.; Agarwal, N. Advanced prostate cancer: Treatment advances and future directions. Trends Cancer, 2020, 6(8), 702-715.
[http://dx.doi.org/10.1016/j.trecan.2020.04.010] [PMID: 32534790]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version368msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[18:04:05] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[18:04:05] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • warninglog[18:04:05] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[18:04:05] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (123ms)time
  • Application (245ms)time
  • 1 x Application (66.59%)
    245ms
    1 x Booting (33.41%)
    123ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    37 statements were executed, 4 of which were duplicates, 33 unique. Show only duplicated150ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('51739267','',1,1739988245,1739988245) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1739988245
      900μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('51739267','/article/116040',1,1739988245,1739988245)
      190μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 51739267 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51739267) limit 1
      26.36msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 51739267
      • 1: 51739267
      • 2: 51739267
      • 3: 51739267
      • 4: 51739267
      • 5: 51739267
      • 6: 51739267
      • 7: 51739267
      • 8: 51739267
      • 9: 51739267
      • 10: 51739267
      • 11: 51739267
      • 12: 51739267
      • 13: 51739267
      • 14: 51739267
      • 15: 51739267
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=116040
      990μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 98 limit 1
      1.1msalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 98
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=98) and sj.journal_id!=98 group by `j`.`nid`) as `aggregate_table`
      1.4msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=98) and sj.journal_id!=98 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.16msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=98) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      1.33msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=98) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      1.28msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '116040'
      2.55msalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 116040
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '116040'
      4.94msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 116040
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '116040' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      2.85msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 116040
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      310μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      700μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 98 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      47.83msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 98 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      9.89msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 98 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      6.35msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 116040 limit 1
      1.33msalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 116040
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 116040 and content_type = 'article' order by status desc limit 1
      470μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 482 and content_id!=116040 and cd.content_type = 'article' order by rand() limit 20
      19.23msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 193950 limit 1
      290μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 193950
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      240μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CMP' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      280μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CMP
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '116040' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      370μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '11194' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      300μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '3236' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      270μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3236) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3236) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3236)
      8.57msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11194) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11194) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 11194)
      600μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 116040) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 116040) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51739267 and j.to_ip >=51739267 )) and ((j.from_date <= 1739988245 and j.to_date >= 1739988245 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 116040)
      550μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '159' and is_uploaded = 1 and issue_id = 11194 order by cast(first_page as SIGNED) desc limit 1
      540μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 159
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '169' and is_uploaded = 1 and issue_id = 11194 order by cast(first_page as SIGNED) asc limit 1
      460μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 169
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      160μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      200μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 116040 limit 1
      2.48msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 116040
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 98 and `b`.`banner_from_date` <= 1739988245 and `b`.`banner_to_date` >= 1739988245 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.5msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 98
      • 3: 1739988245
      • 4: 1739988245
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 98 and `b`.`banner_from_date` <= 1739988245 and `b`.`banner_to_date` >= 1739988245 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.49msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 98
      • 3: 1739988245
      • 4: 1739988245
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='de83e4a60746f9fbe0cde09663e004ea'
      260μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        KGr5omg23RFofpEirglQQJjqoucpDX79dHt80idT
        uc_cart_id
        de83e4a60746f9fbe0cde09663e004ea
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/116040" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/116040
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:8 [ "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        []
        
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Wed, 19 Feb 2025 18:04:05 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6Ilh2bzE1MHRrVU5RMms3V2NlVzc5UGc9PSIsInZhbHVlIjoiQzU3bi8xZis5YWRZaUs3dXU2UWRnWDA5MmY0THF4Tkh3Z2c1Y2UwVUxqalZxMnZJSC96QTRhUGFLUWZDdWtFVkZkZzJlREdFN3V4dk1oUXJDQzNBUjdKZGlBN3ZOUWtmV09hM3gzV1pXVXJVRUpBb1Q3NUxpN1JDbm1qWEhCVmMiLCJtYWMiOiJhNzRhZGYxZWI0Zjc3ZTI3MmIyZWM4NjE5NDZjMjQxM2E4MzE1YzQzODZmYWZlM2E2ZjNjYzUyNjljZTRmYzVkIiwidGFnIjoiIn0%3D; expires=Sat, 22 Feb 2025 06:04:05 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6Ilh2bzE1MHRrVU5RMms3V2NlVzc5UGc9PSIsInZhbHVlIjoiQzU3bi8xZis5YWRZaUs3dXU2UWRnWDA5MmY0THF4Tkh3Z2c1Y2UwVUxqalZxMnZJSC96QTRhUGFLUWZDdWtFVkZkZzJlR" 1 => "alphaeurekaselectnet_session=eyJpdiI6InhGZHNkVHBzZHA3MjBHYVFRVEZiOXc9PSIsInZhbHVlIjoiTk1HOHpkTEgybGlYa29pcDdwNnZpMC91T2tid2pFSzlsNTFEWGRmN0VRUjhibFAvbndMNW1pWU5JelJ4TEo3dmk4L2U5R1hucmRSMG5NWHpmc1k4TmkwK1VReUNjNzUybktvb2x6VWorUExUNnI5alRGelZhcDE4S242NzhBYmgiLCJtYWMiOiIzODgyZTc0ODI5N2ZhNzI0MmE1ZThjMTNlZGNiY2IwOTg4MmE5YTI5OWM4YTcwYTBiZGI5MzhkOTk3NTY1OGM4IiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6InhGZHNkVHBzZHA3MjBHYVFRVEZiOXc9PSIsInZhbHVlIjoiTk1HOHpkTEgybGlYa29pcDdwNnZpMC91T2tid2pFSzlsNTFEWGRmN0VRUjhibFAvbndMNW1pWU5" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6Ilh2bzE1MHRrVU5RMms3V2NlVzc5UGc9PSIsInZhbHVlIjoiQzU3bi8xZis5YWRZaUs3dXU2UWRnWDA5MmY0THF4Tkh3Z2c1Y2UwVUxqalZxMnZJSC96QTRhUGFLUWZDdWtFVkZkZzJlREdFN3V4dk1oUXJDQzNBUjdKZGlBN3ZOUWtmV09hM3gzV1pXVXJVRUpBb1Q3NUxpN1JDbm1qWEhCVmMiLCJtYWMiOiJhNzRhZGYxZWI0Zjc3ZTI3MmIyZWM4NjE5NDZjMjQxM2E4MzE1YzQzODZmYWZlM2E2ZjNjYzUyNjljZTRmYzVkIiwidGFnIjoiIn0%3D; expires=Sat, 22-Feb-2025 06:04:05 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6Ilh2bzE1MHRrVU5RMms3V2NlVzc5UGc9PSIsInZhbHVlIjoiQzU3bi8xZis5YWRZaUs3dXU2UWRnWDA5MmY0THF4Tkh3Z2c1Y2UwVUxqalZxMnZJSC96QTRhUGFLUWZDdWtFVkZkZzJlR" 1 => "alphaeurekaselectnet_session=eyJpdiI6InhGZHNkVHBzZHA3MjBHYVFRVEZiOXc9PSIsInZhbHVlIjoiTk1HOHpkTEgybGlYa29pcDdwNnZpMC91T2tid2pFSzlsNTFEWGRmN0VRUjhibFAvbndMNW1pWU5JelJ4TEo3dmk4L2U5R1hucmRSMG5NWHpmc1k4TmkwK1VReUNjNzUybktvb2x6VWorUExUNnI5alRGelZhcDE4S242NzhBYmgiLCJtYWMiOiIzODgyZTc0ODI5N2ZhNzI0MmE1ZThjMTNlZGNiY2IwOTg4MmE5YTI5OWM4YTcwYTBiZGI5MzhkOTk3NTY1OGM4IiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6InhGZHNkVHBzZHA3MjBHYVFRVEZiOXc9PSIsInZhbHVlIjoiTk1HOHpkTEgybGlYa29pcDdwNnZpMC91T2tid2pFSzlsNTFEWGRmN0VRUjhibFAvbndMNW1pWU5" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "KGr5omg23RFofpEirglQQJjqoucpDX79dHt80idT" "uc_cart_id" => "de83e4a60746f9fbe0cde09663e004ea" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/116040" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-19 18:04:05GET/article/116040414371